Covance plans closures – and expansions – as it aims to 'right-size'

By Melissa Fassbender contact

- Last updated on GMT

LabCorp has expanded its LaunchPad initiative to include Covance Drug Development. (Image: iStock/Pinkypills)
LabCorp has expanded its LaunchPad initiative to include Covance Drug Development. (Image: iStock/Pinkypills)

Related tags: Management

LabCorp’s Covance is implementing a two-phase plan intended to create operational efficiencies over the next three years.

In an SEC filing yesterday, the Laboratory Corporation of America Holdings (LabCorp) announced that it is expanding its LaunchPad business process improvement initiative to include its Covance Drug Development segment.

According to the company, the first phase of the initiative focuses on Covance’s near-term outlook.

Per its earnings release, this phase is expected to generate pre-tax savings of approximately $20m in 2017 and approximately $45m annually thereafter.

In connection with the implementation of the first phase, on April 24, 2017, the Company committed to carry out a reduction in workforce in 2017​,” the SEC filing explained.

In the first phase of this work, there will be a limited number of position reductions across the Covance business​,” Pattie Kushner, a spokesperson for LabCorp told Outsourcing-Pharma.com in a statement.

Additionally, Kushner said the company is “right-sizing​” its operational footprint as part of phase two – “consolidating some facilities while expanding others​,” she said, noting the recent expansion​ at the company’s UK-based operations.

These actions align with our integration strategy, the anticipated flow of client work across our locations and areas targeted for growth​,” she said.

Related facility closure costs are expected to be approximately $16.0m in 2017. 

The second phase focuses on long-term structural changes “designed to create a more efficient business model​,” according to the filing.

However, Kushner said it is import to note that the “vast majority​” of Covance’s 15,000 employees and clients will not be affected by the restructuring and service delivery “will continue without interruption​.”

Those employees who may be impacted have been notified, she said, adding that the actions will be completed by the end of 2017.

More details are expected later in the year.

In the immediate term, our primary focus is to support employees who are transitioning and to work with clients who may have changes in their project teams to avoid any disruption to service​.”

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us

Products

View more

Webinars